N4P has announced its appointment of Nanomerics Limited (‘Nanomerics’) to investigate the potential utility of Nuvec® in cancer therapy.
The project is designed to explore the role of its unique, non-viral adjuvant as a delivery system for DNA and small interfering RNA (‘siRNA’), with an initial aim to test a silica-based, delivery system in a proof of concept (‘POC’) preclinical tumour model (the ‘Oncology Programme’).
Not only could this represent a third commercial application for Nuvec® addressing a giant, unsatisfied and rapidly growing market, but also offer potential to be developed as a combination product capable of carrying an external nucleic acid load and an internal small molecule chemotherapeutic. Utilising Nanomerics’ advanced technologies, that are designed to address bioavailability challenges across a broad range of drugs, including low molecular weight hydrophobics, peptides, and nucleic acid based products, N4P seeks to demonstrate Nuvec‘s novel potential to become a delivery system for oncology therapeutics.
Taken together with its two existing programmes, feasibility work into oral applications and the ongoing technology transfer for Nuvec®’s manufacture, the next six months or so is likely to be pivotal for N4P as a greater understanding of its potential becomes more clearly established.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to N4 Pharma plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2019 Turner Pope Investments (TPI) Limited, all rights reserved.
